CFN Media

February 09, 2017 09:00 ET

Medical Marijuana (MJNA) Secures Alzheimer's Approval in Brazil -- CFN Media

SEATTLE, WA--(Marketwired - Feb 9, 2017) -  CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article covering Medical Marijuana Inc.'s (OTC PINK: MJNA) Real Scientific Hemp Oil (RSHO). The cannabidiol (CBD) hemp oil was recently allowed in Brazil for the treatment of a patient suffering from Alzheimer's disease, further expanding the medical conditions for which Brazil allows the oil to be used.

RSHO is a full-spectrum CBD oil extracted from hemp plants grown in Northern Europe without the use of herbicides, pesticides, or chemical fertilizers, and the final product is triple lab tested at ISO/IEC 1725:2005 accredited food safety labs. Strict EU regulations ensure that the hemp oil is extremely pure prior to export, while the products pass all federal requirements for importation into the U.S. and are available in over 40 countries around the world.

In Latin America, RSHO became the first approved medical cannabis product in Brazil, Mexico and Paraguay, along with the U.S. territory of Puerto Rico. The company has moved both vertically into new countries and horizontally into new medical conditions. Brazil's decision to permit the import of RSHO for the treatment of Alzheimer's disease is just the latest move in a broad expansion of addressable indications across its Latin American end markets.

Cannabidiol has shown promise in treating Alzheimer's disease in a growing number of early-stage studies, according to ProjectCBD. For example, researchers in 2007 inoculated mice with human beta-amyloid peptides -- a hallmark of AD -- and treated them with daily CBDs. The study found that the CBD significantly inhibited the expression of beta-amyloids in a dose-dependent manner and reduced overall neuroinflammation.

The Brazilian government's decision to authorize a doctor's prescription for hemp-based CBD oil for the treatment of Alzheimer's disease acknowledges its potential as a treatment. While more research is needed, the non-toxic nature of hemp-based CBD oil means that patients may be able to realize some benefit before pharmaceutical-grade options are developed and approved, which could prove to be a life-saving decision in some cases.

Please follow the link to read the full article:

Learn how to become a CFN Media featured company, brand or entrepreneur:

Download the CFN Media iOS mobile app to access the world of cannabis from your smart phone:

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:

About CFN Media

CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

About Medical Marijuana Inc.

Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit

To see Medical Marijuana, Inc.'s video statement, click here.

Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.


Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit:

Contact Information